Your Messages Inbox
Your Article Summary
See Latest ArticlesNew Breakthrough Treatment for Advanced Kidney Cancer Shows 49 Per Cent Higher Survival Rates
Corporate News Releases - The Healthcare Sales & Marketing Network, 02/21/08
TORISEL(TM) (temsirolimus), a breakthrough therapy shown to extend median overall survival of patients with metastatic (advanced) renal cell carcinoma (RCC), the most common form of kidney cancer,(1,2) has been approved by Health Canada. TORISEL, which received a priority review from Health Canada, works differently than other cancer therapies. TORISEL is the first and only mTOR-based cancer therapy approved by Health Canada. It specifically inhibits the mTOR (mammalian target of rapamycin) kinase, a type of protein that regulates cell production, cell growth and cell survival.(3,4)
Today in Physician/Patient Trends...keeping you current
Receive free subspecialty "5-minute updates" via email
Trends in hypertension treatment in diabetes
Current Hypertension Reports, 12/09/09
New program helps educate survivors of a heart event about the importance of maintaining good physical and emotional health
Daiichi Sankyo, 12/08/09
Surgical and minimally invasive treatments for Peyronie's disease
Current Opinion in Urology, 11/19/09
Article Search
Sponsor